Cantor Fitzgerald Forecasts Weaker Earnings for Verastem

Verastem, Inc. (NASDAQ:VSTM) – Analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for Verastem in a research report issued to clients and investors on Tuesday, June 24th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the biopharmaceutical company will post earnings of ($3.57) per share for the year, down from their previous forecast of ($3.24). The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem’s FY2026 earnings at ($3.69) EPS.

Verastem (NASDAQ:VSTM) last released its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24).

Several other equities analysts also recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Verastem in a report on Thursday, April 10th. They issued a “buy” rating and a $15.00 price objective on the stock. Wall Street Zen downgraded shares of Verastem from a “hold” rating to a “sell” rating in a research note on Friday, April 18th. Guggenheim upped their price target on shares of Verastem from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, March 24th. Mizuho decreased their price target on shares of Verastem from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 9th. Finally, Royal Bank Of Canada upgraded shares of Verastem from an “outperform” rating to a “moderate buy” rating and decreased their price target for the company from $16.00 to $12.00 in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Verastem currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.38.

Verastem Price Performance

NASDAQ:VSTM opened at $4.16 on Thursday. Verastem has a one year low of $2.10 and a one year high of $9.10. The company has a market cap of $228.59 million, a P/E ratio of -1.30 and a beta of 0.85. The firm’s fifty day moving average price is $6.65 and its two-hundred day moving average price is $5.98. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.50 and a quick ratio of 3.50.

Institutional Investors Weigh In On Verastem

A number of large investors have recently bought and sold shares of VSTM. Tower Research Capital LLC TRC grew its stake in Verastem by 51.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 1,698 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of Verastem in the fourth quarter worth about $56,000. Voya Investment Management LLC bought a new position in shares of Verastem in the fourth quarter worth about $59,000. Sherbrooke Park Advisers LLC bought a new position in shares of Verastem in the fourth quarter worth about $61,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Verastem in the fourth quarter worth about $74,000. 88.37% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Verastem news, CFO Daniel Calkins sold 11,143 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.13, for a total transaction of $90,592.59. Following the sale, the chief financial officer now directly owns 114,055 shares in the company, valued at $927,267.15. This represents a 8.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Dan Paterson sold 17,808 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $5.13, for a total transaction of $91,355.04. Following the sale, the chief executive officer now owns 443,839 shares in the company, valued at $2,276,894.07. The trade was a 3.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,796 shares of company stock worth $693,033 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.